



USSN 10/087,034

CLAIM LISTING


1. (Previously Presented) A compound of the formula Formula (I):



wherein:

 G^1 is a group of formula a

Δ is selected from the group phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, and thienyl, all optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, $-\text{SO}_2\text{R}'$, $-\text{NSO}_2\text{R}'$, $-\text{SO}_2\text{NR}'\text{R}''$, $-\text{NR}'\text{R}''$, or $-\text{COR}'$;
 R' and R'' are each independently hydrogen or lower alkyl;

 G^2 is selected from the group represented by the formula c, d, e, and f

R^1 and R^2 are independently in each occurrence selected from the group consisting of hydrogen, lower alkyl, halogen, haloalkyl, nitro, $-\text{NR}'\text{R}''$, $-\text{OR}'$, $-\text{NR}'\text{SO}_2\text{R}''$, $-\text{SO}_2\text{R}'$, $-\text{COR}'$, cyano, nitro, phenyl (optionally substituted with halo, alkyl, cyano, nitro, or alkoxy), or heteroaryl (optionally substituted with halo, alkyl, cyano, nitro or alkoxy), said heteroaryl having one to three rings, of four to eight atoms per ring, incorporating within each ring one or two heteroatoms

USSN 10/087,034

chosen from nitrogen, oxygen or sulfur; and wherein R¹ and R² are as defined hereinbefore;

R¹ and R², if adjacent, taken together with the carbons to which they are attached may also form an aromatic ring, optionally substituted with one or two substitutents selected from the group consisting of lower alkyl, halo, cyano, or lower alkoxy;

n is an integer selected from 0, 1, 2 and 3;

or pharmaceutically acceptable salts or solvates thereof.

2. (Original) The compound of Claim 1, wherein G² is selected from the group represented by the Formula g and d.
3. (Original) The compound of Claim 1, wherein G² is selected from the group represented by the Formula e and f.
4. (Cancelled)
5. (Cancelled)
6. (Previously Presented) The compound of Claim 2, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO₂R', -NR'SO₂R", -SO₂NR'R", -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.
7. (Original) The compound of Claim 6, wherein G² is a group represented by the Formula g.
8. (Original) The compound of Claim 7, wherein R¹ is hydrogen, lower alkyl, halo, alkoxy, cyano, SO₂R', or COR', and NR'R", and R' and R" are each independently hydrogen or lower alkyl.

USSN 10/087,034

9. (Original) The compound of Claim 7, whercin R¹ is phenyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
10. (Original) The compound of Claim 7, whercin R¹ is pyridinyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
11. (Original) The compound of Claim 7, wherein R¹ is thienyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
12. (Original) The compound of Claim 7, wherein R¹ and R², if adjacent, taken together with the carbons to which they are attached form an optionally substituted aromatic ring, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.

13 - 17. (Cancelled)

18. (Previously Presented) The compound of claim 1, wherein G2 is a group represented by the formula g.
19. (Original) The compound of claim 18, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO₂R', -NR'SO₂R", -SO₂NR'R", -NR'R", or -COR', R¹ is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', -SO₂R', -NR'SO₂R", -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.
20. (Original) The compound of claim 18, wherein A is phenyl optionally substituted lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO₂R', -NR'SO₂R", -SO₂NR'R", -NR'R", or -COR'; R' and R" are each independently hydrogen or lower alkyl; and R¹ is phenyl optionally substituted with halogen, alkyl, cyano, nitro, or alkoxy.

USSN 10/087,034

21 - 28. (Cancelled)

29. (Previously Presented) The compound of claim 1, wherein the compound is selected from the group consisting of:

4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid;

4'-fluoro-4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid;

4'-fluoro-4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid;

2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-naphthalene-1-carboxylic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-isopropoxy-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-6-methyl-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxy- carbonylamino]-5-pyridin-3-yl-benzoic acid;

5-methanesulfonyl-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid;

4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid;

2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-5-thiophen-3-yl-benzoic acid;

5-bromo-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid;

[3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester;

[2-(1H-tetrazol-5-yl)-phenyl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester;

USSN 10/087,034

2-chloro-6-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-naphthalene-1-carboxylic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-methanesulfonylamino-benzoic acid; and


[2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-phenyl]-acetic acid.

30. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in admixture with at least one pharmaceutically acceptable carrier.
31. (Previously Presented) A method of treating a subject with a disease state that is alleviated with an IP antagonist, said disease state selected from asthma and disorders of the urinary tract, said method comprising administering to a subject in need therefor, an effective amount of one or more compounds of Claim 1.
32. (Canceled)
33. (Previously Presented) The method of treatment of claim 31, wherein the disease state comprises bladder disorders associated with bladder outlet obstruction and urinary incontinence conditions.
34. (Canceled)
35. (Canceled)
36. (Previously presented) The method of treatment of claim 31, wherein the disease state comprises asthma.

USSN 10/087,034


37. (Previously Presented) A process for preparing a compound as claimed in Claim 1, which process comprises:

esterification of the compounds having a general Formula 2 or 3:




wherein R^1 and R^2 are as defined in Claim 1,

acylation with phosgene, followed by reaction with a compound of general Formula 2



wherein G^1 is as defined in Claim 1,


and hydrolysis, to provide a compound of the general Formula **Ia** or **Ib**





wherein n , G^1 , R^1 , and R^2 are as defined in Claim 1.

38. (Previously Presented) A process for preparing a compound as claimed in Claim 1, which process comprises:

acylation with phosgene of a compound of general Formula cm or co,



USSN 10/087,034

followed by reaction with a compound of general Formula 2wherein G^1 is as defined herein,and treatment with azide to provide a compound of general Formula 1cwherein n , G^1 , R^1 , and R^2 are as defined herein.